Pancreatic A-Cell Tumor Associated with Severe Diabetes Mellitus

Yoshinaga, Takao; Okuno, Giichi; Yoshitake, Shinji; Tsujii, T.; Nishikawa, Mitsuo

doi:10.2337/diab.15.10.709

Cited by 53 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The histology of metastases usually parallels that of the primary neoplasm. In two instances (6,20), however, cystic foci in the liver were observed, and in two other unrelated cases, primary tumors (10,15) were reported to show cyst formation. In one case (20) both primary and metastatic tumor exhibited cystic changes.…”

Section: Malignancymentioning

confidence: 96%

“…Of 60 cases in which tumor site was recorded, 30 (50%) appeared confined to the region of the tail (5,7,13,15,18,20,24,35,37,50,52,65,66,(71)(72)(73)(74)(75)(76)(77)(78)(79)(80), whereas tumors of the head or neck (4,13,21,37,73,81,82), body (13,18,(83)(84)(85)(86)(87), and body-tail region (3,28,33,68,89,90) were less frequently described. In seven cases multiple tumors (91) or diffuse involvement by a single mass (6,10,32,51,88,92) precluded specific localization of the...…”

Section: Location and Sizementioning

confidence: 97%

“…There is no correlation, however, between circulating insulin and glucagon levels. 2 Patients with glucagonomas usually exhibit a blunted blood glucose response to exogenous glucagon administration (10,34,87,110), and show inconsistent changes to insulin and other hypoglycemic agents (see above). Responsiveness of both hormones to mixed meals, however, appears to remain intact (15,35,51).…”

Section: Hyperglycemiamentioning

confidence: 98%

“…Definitive islet structure or even less precise lobular or glandular elements (33,73,82,105) seldom exist. More commonly, tumor cells are pleomorphic and appear in the form of regular sheets or trabeculae separated by fibrous strands (6,8,10,24,33,51,79,84,94), which may occasionally suggest some degree of orga- …”

Section: Histologymentioning

confidence: 99%

See 3 more Smart Citations

The Glucagonoma Syndrome: Clinical Features, Diagnosis, and Treatment

1981

View full text Add to dashboard Cite

Historical BackgroundIslet cell tumors of the pancreas have been described for over 50 yr. Although carcinoma arising from islet tissue had been noted since the turn of the century (1), not until 1927 was the first case of a hormonally active pancreatic neoplasm, an insulinoma, recorded (2). For many years thereafter, pancreatic endocrine tumors were characterized as either insulin-producing or "nonfunctional," the latter being derived from cells apparently devoid of clinically significant hormonal activity. With time, however, other islet cell secretory products were discovered and their tumors identified with various clinical syndromes. Whereas the hypoglycemia of insulinomas and hyperacidity of gastrinomas figured prominently in the initial recognition of these neoplasms, the clinical signs of glucagon-producing tumors were less readily apparent and not as easily attributable to specific hormone excess.Becker and co-workers (3) are credited with the first description of a glucagonoma. Their case, reported in 1947 but diagnosable only in retrospect, typifies what is now regarded as a classic clinical presentation of the syndrome. The patient, a 45-yr-old woman, sought attention because of a skin rash that, over a period of 8 months, progressed to involve almost her entire body. Weight loss, weakness, and amenorrhea were additional complaints. The rash was symmetrically distributed and characterized by confluent, pruritic areas of macular, erythematous, and vesicular erruptions showing evidence of exfoliation and superficial necrosis. Stomatitis and onchonolysis were also found. Laboratory examination revealed a normochromic anemia, mild fasting hyperglycemia, and hypoproteinemia. Deep venous thrombosis developed while the patient was in hospital, and she succumbed to cardiorespiratory failure. At autopsy, an islet cell neoplasm was discovered "replacing the body

show abstract

Section: Malignancymentioning

confidence: 96%

Section: Location and Sizementioning

confidence: 97%

Section: Hyperglycemiamentioning

confidence: 98%

Section: Histologymentioning

confidence: 99%

See 2 more Smart Citations

The Glucagonoma Syndrome: Clinical Features, Diagnosis, and Treatment

1981

View full text Add to dashboard Cite

show abstract

“…These findings indi cate that not all the patients with the gluca gonoma syndrome course with a high per centage of LGI forms, but that the disease can also be manifested by a massive release into the bloodstream of true glucagon. On the other hand, many cases of the glucagonoma syndrome course with diabetes, which could be related to tumoral destruction of the insu lin-producing tissue, as in the case reported by Yoshinaga et al [1966], and/or could be due to the high circulating levels of glucagon. However, the latter suggestion should be used carefully, because in our patient with high levels of true glucagon and a very low insulin/glucagon ratio only glucose intoler ance was observed, whereas diabetes and even hyperglycemia were absent.…”

Section: Discussionmentioning

confidence: 99%

Secretory Response and Immunochemical Heterogeneity of Glucagon in Plasma and Tumor Extracts of a Patient with Glucagonoma

Torre¹,

Vázquez²,

Blázquez³

1986

Horm Res

View full text Add to dashboard Cite

The secretory response and immunoreactive heterogeneity of glucagon was investigated in a patient with glucagonoma syndrome. After glucose administration, abnormal insulin release accompanied by glucose intolerance were observed, whereas the high glucagon circulating levels were only partially blocked after glucose or somatostatin infusion. Chromatographic fractionation of plasma samples, before and after arginine administration showed that most of the immunoreactivity eluted as true glucagon. Furthermore, when aliquots of the tumor extracts were fractionated by column chromatography or by polyacrylamide gel electrophoresis, most of the immunoreactivity eluted in the 3,500 molecular weight peak. In contrast with previous reports, our results indicate that neoplasia A cells can also manufacture and release into the bloodstream great amounts of genuine glucagon rather than larger glucagon immunoreactive forms. In spite of such findings, in this patient neither diabetes nor hyperglycemia were present.

show abstract

Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases

Verner¹,

Morrison²

1974

Archives of Internal Medicine

View full text Add to dashboard Cite

Pancreatic A-Cell Tumor Associated with Severe Diabetes Mellitus

Cited by 53 publications

References 0 publications

The Glucagonoma Syndrome: Clinical Features, Diagnosis, and Treatment

The Glucagonoma Syndrome: Clinical Features, Diagnosis, and Treatment

Secretory Response and Immunochemical Heterogeneity of Glucagon in Plasma and Tumor Extracts of a Patient with Glucagonoma

Endocrine pancreatic islet disease with diarrhea. Report of a case due to diffuse hyperplasia of nonbeta islet tissue with a review of 54 additional cases

Contact Info

Product

Resources

About